ClinicalTrials.gg
RecruitingNCT06229171InTakeCareUpdated Aug 21, 2025

InTake Care: Development and Validation of an Innovative, Personalized Digital Health Solution for Medication Adherence Support in Cardiovascular Prevention

An interventional study of adherence support system based on a vocal assistant in Hypertension, Treatment Adherence and Compliance and Digital Health, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by Istituto Auxologico Italiano · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Hypertension by Istituto Auxologico Italiano — 5 open to participants now, 5 under way, none of them phase 3. Hypertension · Istituto Auxologico Italiano.

Started
2024
with 1 other
No phase
3 of 14
2 open now
Registered
11th of 14
by date

Among the 14 studies in Hypertension by Istituto Auxologico Italiano, this one is one of 2 that started in 2024, is one of 3 with no phase, and was the 11th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 14 studies in Hypertension by Istituto Auxologico Italiano are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hypertension by Istituto Auxologico Italiano, or all of them as a file.
02

Study summary

Inadequate medication adherence (MA) in chronic conditions, including cardiovascular prevention, represents an important risk factor. The use of new IT technologies in this setting is supposed to be useful to improve patients' adherence, but currently available solutions have significant limitations, including lack of personalization and reliance on expensive ad hoc systems.

This interdisciplinary project aims to verify the hypothesis that in patients on chronic antihypertensive treatment MA can be improved through the implementation of a novel digital health solution for MA monitoring and support, based on inexpensive and user-friendly, commercially available technology (voice assistant), connected with web interface for the physician. The intervention will be personalized based on the creation of Personas, intended as multidisciplinary-based representations of different user types. This approach will be tested in a randomized clinical trial.

03

Conditions studied

  • Hypertension
  • Treatment Adherence and Compliance
  • Digital Health

Keywords

  • Personalized Medicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (>18 years old) patients
  • History of essential hypertension
  • Treatment with at least one antihypertensive drug for which dedicated plasma essay is available
  • wireless internet connection available at patients' home
  • stable clinical conditions
  • written

Exclusion criteria

Exclusion Criteria:

  • insufficient technological literacy to manage vocal assistant
  • dementia or significant psychiatric disorders
  • conditions significantly limiting vocal communication (deafness, significant speech disorders, poor knowledge of Italian language)
  • pregnancy or breastfeeding
  • active cancer (except basal cell skin carcinoma)
  • upper limb amputation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
206 participants (estimated)

Study arms

  • No intervention
    usual practice
  • Experimental
    vocal assistant

    Other: adherence support system based on a vocal assistant

Interventions

  • Otheradherence support system based on a vocal assistant

    Participants in the intervention group will receive a vocal assistant device and the instructions/support for the activation of the system at their homes. The device will remind the participant, at the times defined during set-up, which therapy should be taken and with what dosage. The participant will have 30 minutes from the first reminder to confirm vocally that the therapy has been taken, which will otherwise be considered as not having been taken. Participants in the control group will receive verbal advice from the physician about the need to follow the treatment recommendations and simple indications on possible solutions to maintain adherence, as by the usual practice of the Centre.

06

What researchers measure

Primary outcomes

  1. Adherence (plasma essay - 3m)

    Percentage of adherent patients based on plasma essay at follow-up visit

    Time frame: after 3 months of randomized intervention

Secondary outcomes

  1. adherence (pill count - 3m)

    percentage of adherent patients based on pill count adherence (AdhVA) at follow-up visit

    Time frame: after 3 months of randomized intervention

  2. adherence (voice assistant - 3m)

    percentage of adherent patients based on voice assistant adherence (AdhVA) at follow-up visit

    Time frame: after 3 months of randomized intervention

  3. adherence (questionnaire - 3m)

    percentage of adherent patients based on MARS-5I (Medication Adherence Report Scale-5 Italian version) at follow-up visit

    Time frame: after 3 months of randomized intervention

  4. Adherence (plasma essay - 5m)

    percentage of adherent patients based on plasma essay at final visit

    Time frame: after 5 months

  5. adherence (pill count - 5m)

    percentage of adherent patients based on pill count adherence (AdhVA) at final visit

    Time frame: after 5 months

  6. adherence (voice assistant - 5m)

    percentage of adherent patients based on voice assistant adherence (AdhVA) at final visit

    Time frame: after 5 months

  7. adherence (questionnaire - 5m)

    percentage of adherent patients based on MARS-5I at final visit

    Time frame: after 5 months

  8. 24h Systolic Blood Pressure (3m)

    24-hour systolic blood pressure (ABPM) at follow-up visit

    Time frame: after 3 months of randomized intervention

  9. 24h Systolic Blood Pressure (5m)

    24-hour systolic blood pressure (ABPM) at final visit

    Time frame: after 5 months

07

Study locations

1 of 1 sites recruiting
  • San Luca Hospital, Istituto Auxologico Italiano IRCCS
    Milan, 20149, Italy
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Apr 2026, 18 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 18 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2024
First posted
Jan 29, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Apr 1, 2026
CompletionEst.
Apr 1, 2026
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06229171
Collaborators
Istituti Clinici Scientifici Maugeri SpA, Politecnico di Milano
Responsible party
Sponsor
First posted
Jan 29, 2024
Start date
Oct 1, 2024
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Aug 21, 2025

Study contacts

Grzegorz Bilo, MD, PhD
Contact
g.bilo@auxologico.it
+390261911 ext. 2903
Lucia Zanotti, Bsc, PhD
Contact
l.zanotti@auxologico.it
+390261911 ext. 2714
Grzegorz Bilo, MD, PhD
principal investigator · Istituto Auxologico Italiano

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion